Extended Data Fig. 6: Small molecule targeting of mSWI/SNF complexes inhibits SARS-CoV-2 but not MERS-CoV infection.
From: Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection
(a) Vero E6 cells were treated with 1.25 μM Comp12 for the indicated times, DPP4 transcript level was measured by RT-qPCR. (b) Vero E6 cells were pretreated with Comp12 for 2 days and then infected with MERS-CoV at an MOI of 0.2. Cell viability relative to an uninfected control was measured 3 dpi with CellTiter Glo. (c) Vero E6 cells were pretreated with 1.25 or 2.5 μM Comp12 for 2 days and then infected with VSV pseudovirus (VSVpp): VSVpp-VSV-G, and VSVpp-MERS-S. Luciferase relative to a VSVpp-VSV-G control was measured 1 dpi. (d) Vero E6 and Huh7.5 cells were pre-treated with indicated inhibitors/degraders (2.5 μM) for 2 days prior to infecting with SARS-CoV-2. Virus replication was measured using plaque assay. Dash line, limit of detection. (e) Vero E6 and Huh7.5 cells were pre-treated with indicated inhibitors/degraders (2.5 μM) for 2 days prior to infecting with SARS-CoV-2 pseudovirus to assay for viral entry. Data in (a-e) were analyzed by one-way ANOVA with Tukey’s multiple comparison test. Shown are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, n = 3 biological replicates.
